POLYPHOR AG Spexis to host business update conference call on October 9, 2023
Transparency directive : regulatory news
|
Spexis AG
/ Key word(s): Statement
Spexis to host business update conference call on October 9, 2023
Allschwil, Switzerland, October 6, 2023
Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, announced today that it will host a business update conference call on October 9, 2023, at 8.30am EDT. Jeffrey D. Wager, M.D. (CEO & Chairman) will provide strategic business and financial updates. To access the conference call please use the following details: France: +33 0805102207 International Toll Free +1 412-317-6789
Event Title: Spexis AG – Business Update Conference Call The conference call will also be available via webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=6s6eCE7g After the call, a replay of the webcast will be available via the above link.
About Spexis Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on macrocycle therapeutics for rare diseases and oncology. For further information please visit: www.spexisbio.com.
For further information please contact: For Investors: Or Stephen Jasper
For Media:
End of Media Release |
| Language: | English |
| Company: | Spexis AG |
| Hegenheimermattweg 125 | |
| 4123 Allschwil | |
| Switzerland | |
| Phone: | +41 61 567 1600 |
| Fax: | +41 61 567 1601 |
| E-mail: | info@spexisbio.com |
| Internet: | www.spexisbio.com |
| ISIN: | CH0106213793 |
| Valor: | SPEX |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1742821 |
| End of News | EQS News Service |
|
|
1742821 06.10.2023 CET/CEST